Ensign Pharmaceutical

Ensign Pharmaceutical is a Nebraska-based biotechnology startup focused on developing and commercializing novel localized therapeutics using its proprietary ProGel platform. Founded in 2019 by Dr. Dong Wang, a professor at the University of Nebraska Medical Center (UNMC), the company leverages a thermosensitive polymer-drug conjugate technology that transitions from a liquid at room temperature to a hydrogel at body temperature. This platform enables sustained, localized drug release at the site of pathology, minimizing systemic side effects. Ensign's lead candidate, ProGel-Dex, is a thermoresponsive polymeric dexamethasone prodrug under development for osteoarthritis pain and inflammatory skin conditions like psoriasis. The company's pipeline also features ProGel-HMP, a localized hydromorphone prodrug for skeletal pain, ProGel-SIM for periodontitis, and a macromolecular JAK inhibitor prodrug for ulcerative colitis and rheumatoid arthritis.